Allarity Therapeutics (ALLR) Competitors

Allarity Therapeutics (NASDAQ:ALLR) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Do insiders & institutionals believe in ALLR or IMAB?

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 0.1% of Allarity Therapeutics shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more volatility & risk, ALLR or IMAB?

Allarity Therapeutics has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Is ALLR or IMAB more profitable?

I-Mab's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-369.67%	-100.06%
I-Mab	N/A	N/A	N/A

Which has stronger valuation & earnings, ALLR or IMAB?

Allarity Therapeutics has higher earnings, but lower revenue than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	N/A	N/A	-$11.90M	N/A	N/A
I-Mab	$3.27M	22.66	-$206.44M	N/A	N/A

Do analysts prefer ALLR or IMAB?

I-Mab has a consensus target price of $5.50, suggesting a potential upside of 504.40%. Given I-Mab's stronger consensus rating and higher probable upside, analysts plainly believe I-Mab is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the MarketBeat Community believe in ALLR or IMAB?

I-Mab received 61 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 65.26% of users gave I-Mab an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote.

Company	Underperform	Outperform
Allarity Therapeutics	Outperform Votes 1 50.00%	Underperform Votes 1 50.00%
I-Mab	Outperform Votes 62 65.26%	Underperform Votes 33 34.74%

Does the media favor ALLR or IMAB?

In the previous week, I-Mab had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 4 mentions for I-Mab and 3 mentions for Allarity Therapeutics. I-Mab's average media sentiment score of 0.80 beat Allarity Therapeutics' score of 0.79 indicating that I-Mab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
I-Mab	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

I-Mab beats Allarity Therapeutics on 14 of the 15 factors compared between the two stocks.